Recipharm has made a significant investment into its oral solid development and pilot scale centre in Zwickau.
The German site's expansion will include three new GMP pilot-scale suites, which will be suitable for blending, hard capsule filling and tableting.
This will complement the facility's existing dry and wet granulation technologies, as well as the range of solutions for material science available at the site.
The investment will also incorporate a pilot scale hard capsule filler with mini tablet dosing and dual filling capabilities, as well as a compression & compaction simulator and a pilot scale tablet press.
According to Recipharm, the pilot scale centre focusing on dry technologies will be GMP-ready by early 2025.
With this expansion, Recipharm is now further equipped to deal with:
- API and excipient characterisation
- Product and process development
- Late-stage clinical trial supply
- Batch manufacturing at a small scale
- Scale-up and product optimisation
- Life cycle management
Dr Uwe Hanenberg, Head of Product Implementation, commented: "Our investment into the Zwickau facility will make it more efficient and cost-effective for our customers to access the advice of top experts, while also ensuring their material consumption efficiency."
"With our investment in ReciPredict as well as the GMP pilot scale for dry granulation and now the pilot scale for dry technologies, we have the tools and equipment at hand to support our custom with a faster clinic-to-market timeline for new drugs and de-risking manufacturing, ensuring greater certainty in meeting customer needs."
